Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2024 Aug;60(3):403-404.
doi: 10.1111/apt.18113. Epub 2024 Jun 25.

Editorial: Reading the cholate - A new gateway to portal hypertension and oesophageal varices

Iulia Minciuna  1   2 , Horia Stefanescu  1   2
Affiliations
Editorial

Editorial: Reading the cholate - A new gateway to portal hypertension and oesophageal varices

Iulia Minciuna et al. Aliment Pharmacol Ther. 2024 Aug.
No abstract available

PubMed Disclaimer

Comment in

Comment on

References

REFERENCES

    1. Abraldes JG, Bureau C, Stefanescu H, Augustin S, Ney M, Blasco H, et al. Noninvasive tools and risk of clinically significant portal hypertension and varices in compensated cirrhosis: the “Anticipate” study. Hepatology. 2016;64(6):2173–2184.
    1. de Franchis R, Baveno VI Faculty. Expanding consensus in portal hypertension: report of the Baveno VI consensus workshop: stratifying risk and individualizing care for portal hypertension. J Hepatol. 2015;63(3):743–752.
    1. de Franchis R, Bosch J, Garcia‐Tsao G, Reiberger T, Ripoll C, Baveno VII Faculty. Baveno VII—renewing consensus in portal hypertension. J Hepatol. 2022;76:959–974.
    1. Pons M, Augustin S, Scheiner B, Guillaume M, Rosselli M, Rodrigues SG, et al. Noninvasive diagnosis of portal hypertension in patients with compensated advanced chronic liver disease. Am J Gastroenterol. 2021;116(4):723–732.
    1. Villanueva C, Albillos A, Genescà J, Garcia‐Pagan JC, Calleja JL, Aracil C, et al. β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double‐blind, placebo‐controlled, multicentre trial. Lancet. 2019;393(10181):1597–1608.

MeSH terms

LinkOut - more resources